Psychotic Disorders
Recent clinical, regulatory, research and industry developments relating to this disease.
Adolescent Psychedelic Use and Psychotic or Manic Symptoms.
Implications of Online Self-Diagnosis in Psychiatry.
Using Electronic Health Records to Facilitate Precision Psychiatry.
Psychedelic use and psychiatric risks.
Approval: Invega (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q3 2026.
Clinical MilestonesViewHide
- 2026-04-24A Randomized Controlled Trial With Rituximab for Psychotic Disorder in AdultsResults expected Q3 2026
- 2026-07-30Determination of EEG Microstates Associated With Mental Disorders in At-Risk States (Détermination Des Microétats EEG associés Aux Troubles Psychiques Dans Les États à Risque - DEMETER)Primary completion
- 2025-12-30Accelerated 100Hz Magnetic Seizure Therapy for Psychotic DisordersPrimary completion
- 2026-07-30ClinicalDetermination of EEG Microstates Associated With Mental Disorders in At-Risk States (Détermination Des Microétats EEG associés Aux Troubles Psychiques Dans Les États à Risque - DEMETER)Primary completion
- 2026-04-24ClinicalA Randomized Controlled Trial With Rituximab for Psychotic Disorder in AdultsResults expected Q3 2026
- 2025-12-30ClinicalAccelerated 100Hz Magnetic Seizure Therapy for Psychotic DisordersPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Psychotic Disorders9
- Hallucinogens5
- Psychiatry4
- Alzheimer Disease1
- Bipolar Disorder1
- Cannabis1
- Electronic Health Records1
- Frontotemporal Dementia1
Leading journals6
- Molecular psychiatry2
- Pharmacopsychiatry2
- Psychopharmacology2
- Archives of general psychiatry1
- Biological psychiatry1
- BMC medicine1
Leading researchers8
- Fusar-Poli P2
- McGuire P2
- Osika W2
- Simonsson O2
- Achtyes ED1
- Arribas M1
- Barichello T1
- Bauer M1
Affiliations (unnormalised)6
- University of Oxford4
- Institute of Psychiatry3
- School of Medicine2
- Alfred Hospital1
- Amsterdam University Medical Center1
- and Clinical Sciences1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Psychotic disorders are psychiatric disorders marked by a loss of ego boundaries or a gross impairment in reality testing. They are characterized by delusions or prominent hallucinations.
The supplied literature supports an association between psychosis and childhood adversity, including sexual abuse, physical abuse, emotional or psychological abuse, neglect, parental death, and bullying. It also supports psychosocial stressors as a risk factor for mental illness more broadly, with neuroinflammation proposed as a mediating pathway.
The grounding supports a model in which psychosocial stress may contribute to neuroinflammation, including elevated microglial activity, in the development of mental illness. It also describes psychosis-related mechanisms involving dysregulated thalamic activity, thalamocortical dysrhythmia, altered thalamic filtering of internal and external information, and downstream disruption of cortical network modulation.
Childhood adversity is supported as a risk factor, including abuse, neglect, parental death, and bullying. Psychosocial stressors are also described as a well-documented risk factor for mental illness and are relevant to psychosis in the supplied reviews.
The supplied grounding supports treatment at the level of drug therapy, therapy, and prevention and control, but it does not specify particular modalities or drug classes. It also notes that persons with schizophrenia are often excluded from psychedelic-assisted therapy because of concern about triggering or worsening psychosis, indicating that psychedelics are not standard treatment in this context.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.